NCT00638222终止不适用
Carvedilol and Micro T-Wave Alternans in Hypertensives With Chronic Kidney Disease
University of Toledo Health Science Campus4 个研究点 分布在 1 个国家目标入组 6 人开始时间: 2008年5月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 发起方
- 入组人数
- 6
- 试验地点
- 4
- 主要终点
- Micro T- Wave Alternans
研究概览
简要总结
Evaluate effectiveness of Carvedilol CR on Micro T-Wave Alternans in high risk hypertensives
详细描述
The effect of Carvedilol CR on Micro T-Wave Alternans will be assessed in 30 hypertensives with stage 4 or 5 chronic kidney disease utilizing a cross-over design and contrasting no treatment against active treatment periods of 8 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Prevention
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adults age 18 and older
- •Chronic kidney disease
- •Must be able to do stress test
排除标准
- •Must not be mentally disabled
- •Unable to provide informed consent
- •Unable or unwilling to comply with study protocol or procedures
- •Pregnancy or unknown pregnancy status in female of childbearing potential
- •Participation in any drug trial during the study period
- •Prior enrollment in this study
- •Active liver disease
- •Currently on β-blocker medication at the time of enrollment
- •Known history of asthma exacerbation with β-blocker therapy
- •Second or third degree AV nodal block or bradycardia with resting heart rate <50 bpm
- •Prior allograft organ transplantation
- •Planned allograft transplantation reasonably foreseen within the active treatment period
- •Electrocardiographic left or right bundle branch block
- •Permanent implanted pacemaker
- •Atrial fibrillation
- •Ongoing treatment with any of the following medications: sotalol (Betapace), azimilide (Stedicor), quinidine (Quinidex), disopyramide (Norpace), dofetilide (Tikosyn), ibutilide (Corvert), procainamide (Procanbid), bepridil (Vascor), amiodarone (Cordarone), clarithromycin (Biaxin), erythromycin (Eryc), halofantrine (Halfan), pentamidine (Pentam), sparfloxacin (Zagam), domperidone (Motilium), droperidol (Inapsine), chlorpromazine (Thorazine), haloperidol (Haldol), mesoridazine (Serentil), thioridazine (Mellaril), pimozide (Orap), arsenic trioxide (Trisenox), cisapride (Propulsid), lidoflazine (Clinium), and methadone (Dolophine)
结局指标
主要结局
Micro T- Wave Alternans
时间窗: week 1, 8, 11, 18
次要结局
- Interleukin-6(week 1, 8, 11, 18)
- Plasma C-reactive Protein(week 1, 8, 11, 18)
- Plasma Cardiac Troponin T(week 1, 8, 11, 18)
- Plasma NT-pro BNP(week 1, 8, 11, 18)
- Plasma F2-isoprostanes(week 1, 8, 11, 18)
- Oxidized LDL(week 1, 8, 11, 18)
研究者
Christopher Cooper, MD
Professor, Interim Chair/Dir Cardiovas Research Cntr
University of Toledo Health Science Campus
研究点 (4)
Loading locations...
相似试验
Unknown
不适用
Carvedilol for Prevention of Esophageal Varices ProgressionCirrhosis, LiverPortal HypertensionNCT03736265Beijing Friendship Hospital240
终止
4 期
Vascular Benefits of Adding CarvedilolCR to Type2 Diabetic Patients on ACEI.HypertensionDiabetes Mellitus, Type 2NCT00430040University at Buffalo14
Unknown
3 期
Endoscopic and Microbiological Assessment of the Effect of Carvedilol Combined With Berberine on GOV in CirrhosisCirrhosis Due to Hepatitis BCirrhosis Due to Hepatitis CGastroesophageal VaricesNCT04543643Tianjin Second People's Hospital288
已完成
3 期
The Vascular Effects of Carvedilol Controlled Release (CR) in Abdominally Obese Hypertensive PatientsAbdominal ObesityHypertensionNCT00459056St. Paul Heart Clinic25
已完成
不适用
KF2022#4-trial: Effects of a Beta Blocker and NSAID on CYP Mediated Drug MetabolismDrug InteractionNCT06566794Helsinki University Central Hospital12